Bullish indicating open at $55-$60, IPO prices at $37
CAMBRIDGE, Mass. - Ernexa Therapeutics, a biotech company listed on NASDAQ:ERNA with a market capitalization of $11.05 million, announced at the AACR Annual Meeting 2025 in Chicago on Tuesday that its latest study showed promising results for an innovative cell therapy in treating ovarian cancer. The company’s stock has shown significant volatility, with a notable 14.8% return over the past week, though it remains 88% below its year-ago levels. According to InvestingPro analysis, the stock is currently trading near its Fair Value. The company’s research demonstrated that engineered cells derived from stem cells could significantly slow tumor growth and improve the immune system’s ability to fight cancer.
The study, led by Dr. Michael Andreeff from The University of Texas MD Anderson Cancer Center, revealed that induced mesenchymal stem cells (iMSCs), which were engineered to secrete immune-boosting cytokines IL-7 and IL-15, not only shrank tumors in mice but also increased the presence of immune cells such as T cells, natural killer (NK) cells, and macrophages within the tumors. These iMSCs also promoted the growth and multiplication of T cells, proving effective even against drug-resistant cancer cells.
Ernexa’s lead product, ERNA-101, harnesses this technology and has shown significant promise in preclinical trials for becoming a more effective, accessible, and scalable treatment option for ovarian cancer patients. The company’s approach involves transforming induced pluripotent stem cells (iPSCs) into iMSCs, creating allogeneic synthetic iMSCs that provide an off-the-shelf treatment solution without the need for patient-specific cell harvesting.
The data builds on prior research by Dr. Andreeff that highlighted the potential of mesenchymal stem cells in cancer treatment, addressing previous challenges such as their immune-suppressing nature. The study’s findings support Ernexa’s commitment to advancing cancer treatment through innovative therapies. While the company has demonstrated impressive revenue growth of 756% in the last twelve months, InvestingPro data reveals it holds more cash than debt on its balance sheet, though it’s currently burning through cash reserves. Get access to 15+ additional ProTips and comprehensive financial metrics with InvestingPro.
Ernexa Therapeutics focuses on developing cell therapies for advanced solid tumors and autoimmune diseases. Aside from ERNA-101, the company is also developing ERNA-102, a cell therapy product targeting inflammation for the treatment of autoimmune diseases.
The company’s forward-looking statements, as mentioned in the press release, are subject to risks and uncertainties, including the progress and possible outcomes of its lead research project, ERNA-101, and future research projects. With the next earnings report due in 14 days, analysts do not anticipate profitability this year, projecting an EPS of -$0.92 for FY2025. Discover detailed financial analysis and real-time updates with InvestingPro’s comprehensive coverage. These statements are based on current expectations and are qualified by cautionary notes advising not to place undue reliance on them, as actual results may differ materially.
This news article is based on a press release statement from Ernexa Therapeutics.
In other recent news, Eterna Therapeutics Inc. has announced a significant capital raise through a private placement agreement with accredited investors. The company sold 58.3 million shares of common stock and pre-funded warrants to purchase up to 11 million shares, with the initial sale involving approximately 10 million shares and 510,000 pre-funded warrants. This transaction represents 19.99% of Eterna’s outstanding shares, with a second transaction contingent upon shareholder approval. Additionally, Eterna has rescheduled its 2025 annual meeting of stockholders to June 2, 2025, allowing stockholders to submit nominations and proposals by April 13, 2025.
In a corporate update, Eterna Therapeutics has rebranded itself as Ernexa Therapeutics Inc., effective March 26, 2025, as per a filing with the Secretary of State of Delaware. The rebranding includes an amendment to its Restated Certificate of Incorporation and updated bylaws to reflect the new corporate identity. This name change does not affect the company’s business operations, management, or location.
Furthermore, Eterna Therapeutics had initially scheduled its 2025 annual meeting of stockholders for May 1, 2025, requiring early notification for shareholder proposals and director nominations by February 23, 2025. This early scheduling aims to provide adequate time for preparing and distributing proxy materials. The company’s adherence to Exchange Act Rule 14a-11 ensures compliance with regulations governing shareholder nominations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.